Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based antinicotine vaccine

Human Gene Therapy

Volumn 24, Issue 6, 2013, Pages 595-603

  Rosenberg, Jonathan B ^a   De, Bishnu P ^a   Hicks, Martin J ^a   Janda, Kim D ^b   Kaminsky, Stephen M ^a   Worgall, Stefan ^a   Crystal, Ronald G ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS HEXON PROTEIN; HAPTEN; HEXONAM1; NICOTINE; NICOTINE HAPTEN AM1; NICOTINE VACCINE; PHOSPHATE BUFFERED SALINE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; IMMUNIZATION; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; SEROTYPE;

ANIMALS; ANTIBODIES; BRAIN; CAPSID PROTEINS; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NICOTINE; TOBACCO USE DISORDER; VACCINATION; VACCINES;

ADENOVIRIDAE; MIRIDAE; MUS;

EID: 84879171193     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2012.245     Document Type: Article

References (57)

1. Adhikari, B., Kahende, J., Malarcher, A., et al. (2008). Smokingattributable mortality, years of potential life lost, and productivity losses-United States, 2000-2004.
2. MMWR Morb. Mortal. Wkly. Rep. 57, 1226-1228.
3. Benowitz, N.L. (1996). Pharmacology of nicotine: addiction and therapeutics. Annu. Rev. Pharmacol. Toxicol. 36, 597-613.
4. Carrera, M.R., Ashley, J.A., Parsons, L.H., et al. (1995). Suppression of psychoactive effects of cocaine by active immunization. Nature 378, 727-730.
5. Carrera, M.R., Ashley, J.A., Hoffman, T.Z., et al. (2004). Investigations using immunization to attenuate the psychoactive effects of nicotine. Bioorg. Med Chem. 12, 563-570.
6. Cerny, E.H. and Cerny, T. (2009). Vaccines against nicotine. Hum. Vaccin. 5, 200-205.
7. Cerny, E.H., Levy, R., Mauel, J., et al. (2002). Preclinical development of a vaccine 'against smoking'. Onkologie 25, 406-411.
8. Cerny, T. (2005). Anti-nicotine vaccination: where are we? Recent Results Cancer Res. 166, 167-175.
9. Chugh, B.P., Lerch, J.P., Yu, L.X., et al. (2009). Measurement of cerebral blood volume in mouse brain regions using microcomputed tomography. Neuroimage. 47, 1312-1318.
10. Collins, A.C. and Marks, M.J. (1989). Chronic nicotine exposure and brain nicotinic receptors-influence of genetic factors. Prog. Brain Res. 79, 137-146.
11. Collins, A.C., Miner, L.L., and Marks, M.J. (1988). Genetic influences on acute responses to nicotine and nicotine tolerance in the mouse. Pharmacol. Biochem. Behav. 30, 269-278.
12. Cornuz, J., Zwahlen, S., Jungi, W.F., et al. (2008). A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One 3, e2547.
13. Fellows, J.L., Trosclair, A., Adams, E.K., et al. (2002). Annual smoking-attributable mortality, years of potential life lost, and economic costs-United States, 1995-1999.
14. MMWR Morb. Mortal. Wkly. Rep. 51, 300-303.
15. Fiore, MC, Jaen, C.R., Baker, T.B., et al. (2008). Overview and Methods. In Treating Tobacco Use and Dependence: 2008 Update, (Rockville, MD: US Department of Health and Human Services), pp. 11-34.
16. Haase, A.T., Mautner, V., and Pereira, H.G. (1972). The immunogenicity of adenovirus type 5 structural proteins. J. Immunol. 108, 483-485.
17. Hartmann-Boyce, J., Cahill, K., Hatsukami, D., et al. (2012). Nicotine vaccines for smoking cessation. Cochrane Database Syst. Rev. 8, CD007072.
18. Hatsukami, D.K., Rennard, S., Jorenby, D., et al. (2005). Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin. Pharmacol. Ther. 78, 456-467.
19. Hatsukami, D.K., Jorenby, D.E., Gonzales, D., et al. (2011). Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin. Pharmacol. Ther. 89, 392-399.
20. Hicks, M.J., De, B.P., Rosenberg, J.B., et al. (2011). Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs. Mol. Ther. 19, 612-619.
21. Hicks, M.J., Rosenberg, J.B., De, B.P., et al. (2012). AAV-directed persistent expression of a gene encoding anti-nicotine antibody for smoking cessation. Sci. Transl. Med. 4, 140ra87.
22. Hughes, J.R. (2003). Motivating and helping smokers to stop smoking. J Gen. Intern. Med. 18, 1053-1057.
23. Kasel, J.A., Couch, R.B., and Douglas, R.G., Jr. (1971). Antigenicity of alum and aqueous adenovirus hexon antigen vaccines in man. J. Immunol. 107, 916-919.
24. King, B., Dube, S., Kaufmann, R., et al. (2011). Vital signs: current cigarette smoking among adults aged >/= 18 years-United States, 2005-2010.
25. MMWR Morb. Mortal. Wkly. Rep. 60, 1207-1212.
26. Kinsey, B.M., Jackson, D.C., and Orson, F.M. (2009). Anti-drug vaccines to treat substance abuse. Immunol. Cell Biol. 87, 309-314.
27. Kosten, T. and Owens, S.M. (2005). Immunotherapy for the treatment of drug abuse. Pharmacol. Ther. 108, 76-85.
28. Kramp, W.J., Six, H.R., Drake, S., et al. (1979). Liposomal enhancement of the immunogenicity of adenovirus type 5 hexon and fiber vaccines. Infect. Immun. 25, 771-773.
29. LeSage, M.G., Keyler, D.E., and Pentel, P.R. (2006). Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies. AAPS J. 8, E65-E75.
30. Liepold, L., Anderson, S., Willits, D., et al. (2007). Viral capsids as MRI contrast agents. Magn. Reson. Med. 58, 871-879.
31. Marks, M.J., Romm, E., Bealer, S.M., et al. (1985). A test battery for measuring nicotine effects in mice. Pharmacol. Biochem. Behav. 23, 325-330.
32. Matthews, Q.L., Yang, P., Wu, Q., et al. (2008). Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach. Virol. J. 5, 98.
33. Matthews, Q.L., Fatima, A., Tang, Y., et al. (2010). HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach. PLoS One 5, e11815.
34. Maurer, P. and Bachmann, M.F. (2007). Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert Opin. Investig. Drugs 16, 1775-1783.
35. Maurer, P., Jennings, G.T., Willers, J., et al. (2005). A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur. J. Immunol. 35, 2031-2040.
36. McConnell, M.J., Danthinne, X., and Imperiale, M.J. (2006). Characterization of a permissive epitope insertion site in adenovirus hexon. J. Virol. 80, 5361-5370.
37. Molinier-Frenkel, V., Lengagne, R., Gaden, F., et al. (2002). Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J. Virol. 76, 127-135.
38. Moreno, A.Y., Azar, M.R., Warren, N.A., et al. (2010). A critical evaluation of a nicotine vaccine within a self-administration behavioral model. Mol. Pharm. 7, 431-441.
39. Neurath, A.R., Stasny, J.T., and Rubin, B.A. (1970). Disruption of adenovirus type 7 by lithium iodide resulting in the release of viral deoxyribonucleic acid. J. Virol. 5, 173-178.
40. Nides, M. (2008). Update on pharmacologic options for smoking cessation treatment. Am. J. Med. 121, S20-S31.
41. Office of the Surgeon General. (2010). How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. 2010. Atlanta, GA, US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
42. Palma, C., Overstreet, M.G., Guedon, J.M., et al. (2011). Adenovirus particles that display the Plasmodium falciparumcircumsporozoite protein NANP repeat induce sporozoiteneutralizing antibodies in mice. Vaccine 29, 1683-1689.
43. Pentel, P.R., Malin, D.H., Ennifar, S., et al. (2000). A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol. Biochem. Behav. 65, 191-198.
44. Picciotto, M.R. (2003). Nicotine as a modulator of behavior: beyond the inverted U. Trends Pharmacol. Sci. 24, 493-499.
45. Polosa, R. and Benowitz, N.L. (2011). Treatment of nicotine addiction: present therapeutic options and pipeline developments. Trends Pharmacol. Sci. 32, 281-289.
46. Raupach, T., Hoogsteder, P.H., and Onno van Schayck, C.P. (2012). Nicotine vaccines to assist with smoking cessation: current status of research. Drugs 72, e1-16.
47. Rosenfeld, M.A., Yoshimura, K., Trapnell, B.C., et al. (1992). In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68, 143-155.
48. Singh, R. and Kostarelos, K. (2009). Designer adenoviruses for nanomedicine and nanodiagnostics. Trends Biotechnol. 27, 220-229.
49. Stolerman, I.P. and Jarvis, M.J. (1995). The scientific case that nicotine is addictive. Psychopharmacology (Berl.) 117, 2-10.
50. Sumida, S.M., Truitt, D.M., Lemckert, A.A., et al. (2005). Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J. Immunol. 174, 7179-7185.
51. Suzuki-Kouyama, E., Katayama, K., Sakurai, F., et al. (2011). Hexon-specific PEGylated adenovirus vectors utilizing avidinbiotin interaction. Biomaterials 32, 1724-1730.
52. Vasalatiy, O., Gerard, R.D., Zhao, P., et al. (2008). Labeling of adenovirus particles with PARACEST agents. Bioconjug. Chem. 19, 598-606.
53. Wagena, E.J., de, V.A., Horwith, G., et al. (2008). The immunogenicity and safety of a nicotine vaccine in smokers and nonsmokers: results of a randomized, placebo-controlled phase 1/2 trial. Nicotine Tob. Res. 10, 213-218.
54. World Health Organization. (2009). WHO Report on the Global Tobacco Epidemic, 2009: Implementing smoke-free environments. (France: WHO Library Cataloguing-in-Publication Data).
55. Worgall, S., Krause, A., Rivara, M., et al. (2005). Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid. J. Clin. Invest 115, 1281-1289.
56. Yoshioka, Y., Asavatanabodee, R., Eto, Y., et al. (2008). Tat conjugation of adenovirus vector broadens tropism and enhances transduction efficiency. Life Sci. 83, 747-755.
57. Youil, R., Toner, T.J., Su, Q., et al. (2002). Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum. Gene Ther. 13, 311-320.